SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

Nonja is trending as community members highlight its strong performance within the Injective ecosystem and discuss its potential for significant gains, particularly with upcoming Injective upgrades and ETF possibilities. Community members emphasize Nonja's strong community, high burned liquidity, and successful NFT collections, positioning it as a leading meme coin on the Injective blockchain. Discussions also focus on its potential for high returns and its solid chart as positive factors.

this coin is scarce

SCARCE CRYPTO is trending as traders discuss its potential for a breakout, citing a tightening chart and accumulation by larger holders. The community emphasizes its low supply and is watching closely for a significant move, with some comparing it to other Solana-based tokens.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is gaining traction as the community rallies behind its vision within the Bitcoin ecosystem, particularly its role in the Rune revolution. Discussions highlight its potential to drive a Bitcoin-native culture and its commitment to a fair, community-driven approach, with some anticipating upcoming catalysts like ZAP integration.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending as the community highlights its potential for scaling Bitcoin and Zcash, creating a "Ztarknet" for privacy and scalability. Recent upgrades and incentives for Bitcoin liquidity staking are driving interest, with some seeing it as a key player in Layer 2 solutions. Discussions also focus on the technology's potential for enabling advanced dApps and its ties to zero-knowledge proofs.

GraniteShares ETF Trust - GraniteShares 2x Long MARA Daily ETF

GraniteShares 2x Long MARA Daily ETF

GraniteShares 2x Long MARA Daily ETF (MRAL) is trending as traders discuss its leveraged exposure to MARA, a Bitcoin mining company. Community members are weighing rate cut expectations and upcoming earnings, with some opting to swap MARA shares for MRAL to amplify potential gains. There's considerable chatter about MARA's Bitcoin holdings and potential impact on earnings.

Royal Bank of Canada engages in the provision of banking and financial services. It operates through the following segments: Personal and Commercial Banking, Wealth Management, Insurance, Capital Markets, and Corporate Support. The Personal and Commercial Banking segment deals with a broad suite of financial products and services in both individual and business clients in Canada, the Caribbean, and the U.S. The Wealth Management segment offers a suite of wealth, investment, trust, banking, credit, and other advice-based solutions. It also offers other wealth management solutions to institutional and individual clients through its distribution channels and third-party distributors. The Insurance segment refers to a suite of advice and solutions for individual and business clients including life, health, wealth, property and casualty, travel, group benefits, annuities, and reinsurance. The Capital Markets segment is involved in the provision of advisory and origination, sales and trading, lending and financing and transaction banking to corporations, institutional clients, asset managers, private equity firms and governments globally. The Corporate Support segment consists of technology and operations services. The company was founded by J. W. Merkell, Edward Kenny, T. C. Kinnear, James B. Duffus, William Cunard, John Tobin, George P. Mitchell and Jeremiah Northup in 1864 and is headquartered in Toronto, Canada.

Royal Bank Of Canada

Royal Bank of Canada ($RY) is garnering attention due to Elliott Wave analysis suggesting a potential rally continuation before a larger pullback, with some analysts eyeing specific upside targets. Community discussions revolve around identifying the peak of this bullish wave and preparing for a subsequent corrective phase. Recent data indicates resilient consumer spending and stabilization in the housing market, further influencing investor sentiment.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium (CCD) is gaining attention as a privacy-focused, regulation-friendly layer-1 blockchain, with community members highlighting its potential for real-world adoption and compliant stablecoin payments. Recent partnerships with Ledger and bitcoin.com/ are driving increased interest, as users speculate on its potential to disrupt the PayFi space. The community emphasizes CCD's focus on verifiable trust and on-chain identity, positioning it as a key infrastructure play for the future of regulated DeFi.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum (ARB) is trending as the community discusses its potential for tokenizing real-world assets, particularly with Robinhood and PayPal utilizing the platform. Discussions revolve around Arbitrum's position as a leading layer-2 solution for Ethereum, offering scalability and efficiency. Some community members are pointing out its undervalued status compared to other blockchains.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as community members discuss its potential, technological advantages, and future price targets. Despite some concerns about short-term price action and exchange listings, there is optimism about upcoming smart contracts and their potential impact. The community also notes Kaspa's unique attributes, such as its fair launch and fast transaction speeds.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTER is trending as the crypto community discusses its resilience amid a red market and news around buybacks. Some believe the coin is primed for a run, fueled by speculation around CZ's involvement, while others are wary of potential manipulation and dilution. Community members are weighing the potential of ASTER as a decentralized exchange against concerns of centralization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Meets Q1 Earnings Estimates

Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations">said.</a> The strategic restructuring is aimed at aligning resources to complete the late-stage trial of Mavorixafor in patients with moderate and severe chronic neutropenia, it added.Shares of the company traded 0.5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/XFOR">XFOR stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.The Boston-headquartered firm announced that Chief Legal and Compliance Officer Natasha Thoren, Chief Operating Officer Mary DiBiase, and Chief Commercial Officer Mark Baldry will be exiting the company as part of the workforce reduction. Chief Medical Officer Christophe Arbet‑Engels, meanwhile, is resigning for personal reasons, it added.“Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well-positioned to become a world‑class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia,” said Executive Chairman Adam Craig.The company also appointed its President, John Volpone, as the COO, and he will now oversee day‑to‑day operational management and business execution in his expanded role. Craig, meanwhile, will oversee clinical development.The company’s Mavorixafor is marketed as Xolremdi in the U.S. for the treatment of people aged 12 years and older with WHIM syndrome — a rare, primary immunodeficiency disorder that impairs white blood cell movement from the bone marrow to the bloodstream. The company is now evaluating additional uses of Mavorixafor and is conducting a global, pivotal late-stage clinical trial in people with certain chronic neutropenic disorders. Neutropenia is characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections.XFOR stock is down by about 85% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.

Equity

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.


X4 Pharmaceuticals (XFOR) on Wednesday announced the closing of an upsized private placement of over 11 million shares of common stock and pre-funded warrants to purchase nearly 49 million shares of common stock for total offering proceeds of $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-closing-upsized-85-million-private">said</a> that the originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment right.<a href="https://stocktwits.com/symbol/XFOR">X4</a> intends to use the net proceeds from the offering for continued development towards a potential additional approval of Mavorixafor in chronic neutropenia, in addition to the commercialization of the drug for the treatment of WHIM syndrome.On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_9_57_21_AM_png_cea6672fbd.webp" alt="XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="631" height="61"><figcaption>XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the placement and the additional funding.<stembedurl>https://stocktwits.com/Sir_Falstaff/message/624932917</stembedurl>However, another user opined that the stock would trade 200% higher if the news were that positive.<stembedurl>https://stocktwits.com/FreedoniaT/message/624925751</stembedurl>H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target for the XFOR stock to $3.50 from $7 and kept a ‘Buy’ rating on the shares, according to The Fly.The firm updated the company's model to reflect the second-quarter (Q2) report and the private placement. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst told investors in a research note.X4 on Tuesday announced that its President and Chief Executive Officer, Paula Ragan, and Chief Financial Officer Adam Mostafa have stepped down from their respective roles.X4 Board of Directors appointed Adam Craig as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer, effective immediately.XFOR stock is down 86% this year and 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ppi-report-wall-street-awaits-wholesale-inflation-data-for-cues-fed-rate-cut/chrCQjNRd9J">PPI Report: Wall Street Awaits Wholesale Inflation Data For Further Cues On Fed’s Rate Path Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right.

X4 Pharmaceuticals Unveils Corporate Presentation for Investors

X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

Investors considering a purchase of X4 Pharmaceuticals Inc (XFOR) shares, but tentative about paying the going market price of 1.40/share, might benefit from considering selling puts among the...

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XFOR News

XFORX4 Pharmaceuticals Inc